CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine

Pharmacogenomics Journal

Volumn 8, Issue 6, 2008, Pages 416-422

  Kreutz, R ^a   Bolbrinker, J ^a   van der Sman de Beer, F ^b   Boeschoten, E W ^c   Dekker, F W ^b   Kain, S ^a   Martus, P ^a   Sietmann, A ^d   Friedrichs, F ^d   Stoll, M ^d   Offermann, G ^a   Beige, J ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Hans Mak Institute   (Netherlands)

^d Leibniz Institut für Arterioskleroseforschung   (Germany)

^e Klinikum St Georg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A5; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; GASTROINTESTINAL AGENT; INSULIN; IRON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATE BINDING AGENT; PREDNISOLONE; VASODILATOR AGENT; VITAMIN; WARFARIN;

ADULT; ALLELE; ARTICLE; CADAVER KIDNEY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GENE LOCUS; GENOTYPE; HAPLOTYPE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME;

COHORT STUDIES; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SURVIVAL ANALYSIS;

EID: 56349119899     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500488     Document Type: Article

References (31)

1. Calne R. Cyclosporine as a milestone in immunosuppression. Transplant Proc 2004; 36(Suppl 2): 13S-15S.
2. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004; 26: 192-199.
3. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
4. Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG et al CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95: 1297-1300.
5. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J et al. Coregulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-172.
6. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Chaib Eddour D et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant recipients. Pharmacogenetics 2004; 14: 147-154.
7. Cheung CY, Op den Buijsch RA, Wong KM, Chan HW, Chau KF, Li CS et al Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics 2006; 7: 563-574.
8. Chu XM, Hao HP, Wang GJ, Guo LQ, Min PQ. Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients. Acta Pharmacol Sin 2006; 27: 1504-1508.
9. Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De MM, Eddour DC et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study. Am J Transplant 2006; 6: 2706-2713.
10. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 2006; 33: 1093-1098.
11. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81: 228-234.
12. Thompson EE, Kuttab-Boulos H, Yang L, Roe BA, Di RA. Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 2006; 6: 105-114.
13. Thummel KE. A genetic test for immunosuppressant dose selection? Pharmacogenetics 2004; 14: 146.
14. Wang HP, Xie JJ, Zhang ZY, Ying Y, Zhu ZG, Mao P. Study on polymorphisms of CYP3A5 gene and their clinical role]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005; 22: 423-426.
15. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006; 2: 171-182.
16. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 2004; 68: 1889-1902.
17. Christians U, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 1995; 28: 547-559.
18. Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 2004; 14: 665-671.
19. Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. Nat Med 2001; 7: 285-287.
20. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50: 52-59.
21. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501-1511.
22. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505.
23. Sim SC, Edwards RJ, Boobis AR, Ingelman-Sundberg M. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics 2005; 15: 625-631.
24. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883-891.
25. Min DI, Ellingrod VL. Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2003; 25: 305-309.
26. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545-556.
27. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207-213.
28. van der Sman-de Beer F, Verhagen C, Rombach SM, Boorsma P, van Manen JG, Korevaar JC et al. ACE I/D polymorphism is associated with mortality in a cohort study of patients starting with dialysis. Kidney Int 2005; 68: 2237-2243.
29. Ranade K, Chang MS, Ting CT, Pei D, Hsiao CF, Olivier M et al. High-throughput genotyping with single nucleotide polymorphisms. Genome Res 2001; 11: 1262-1268.
30. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005; 338: 299-305.
31. Hesselink DA, van Schaik RH, van der Heiden IP, van der WM, Gregoor PJ, Lindemans J et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.